Marisa Piccirillo

Dr. Marisa Piccirillo


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2025 in Microorganisms
Verified
Journal Article
Open access
PDF file
VGValentina Giorgio
Valentina Giorgio
GQGiovanna Quatrale
Giovanna Quatrale
MMMaurizio Mennini
Maurizio Mennini
MPMarisa Piccirillo
Marisa Piccirillo
SFSilvia Furio
Silvia Furio
Giovanni Di NardoGiovanni Di Nardo
Giovanni Di Nardo
The gut microbiota plays a pivotal role in gastrointestinal inflammation and immune response since changes in microbiota may result in abnormal neurotransmitter expression, inducing changes in gastrointestinal sensory–motor function and leading to symptom onset in irritable bowel syndrome (IBS) patients. The Bifidobacterium adolescentis species has a documented immunomodulatory effect through its ability to produce γ-aminobutyric acid (GABA), the primary inhibitory neurotransmitter in the mammalian central nervous system, which is reduced in IBS patients. This is a multicentric, randomized, double-blind, placebo-controlled, parallel-arm trial aimed at evaluating the effectiveness of Bifidobacterium adolescentis PRL2019 in children with IBS. IBS children diagnosed according to Rome IV criteria were enrolled and randomized into two groups to receive one stick containing 20 × 109 colony-forming unit of Bifidobacterium adolescentis PRL2019 (Gabapral, Pontenure, Italy) or an equivalent placebo once a day, in a 1:1 ratio, for 12 weeks. Clinical evaluation of symptoms was performed every four weeks using validated scores. Bowel habit characteristics were assessed using the Bristol Stool Chart (BSC). Seventy-two subjects (mean age 12.2 ± 1.8 years, 30 males) were enrolled and randomized into two groups, each of thirty-six patients. No significant differences were observed between the two groups regarding demographic characteristics, distribution of IBS subtypes, or baseline measures of IBS severity and BSC. The proportion of patients achieving complete remission was significantly higher in the BA Group (19/36; 52.8%) than in the Placebo Group (7/36; 19.4%, p = 0.003, odds ratio [OR] 0.216, 95% confidence interval [CI] 0.075–0.619). Both groups obtained a reduction in Total IBS Symptom Severity Scale (IBS SSS), Pain Intensity Score (PIS), Pain Frequency Score (PFS), and Life Interference Score (LIS) from T0 to T12. However, upon intergroup comparison, only in the BA group did the IBS-SSS (p = 0.001), PIS (p = 0.001), LIS (p = 0.015), and PFS (p = 0.005) significantly improve between T0 and T12. BSC showed a greater representation of normal stools (type 3–4) at the end of treatment in the BA group compared with baseline (25% vs. 58.3%, p = 0.004), especially in patients who presented an IBS–constipation subtype at T0 (44.5% vs. 19.4%, p = 0.02). In our study, Bifidobacterium adolescentis PRL2019 reduces the severity and frequency of symptoms in children with IBS, positively affecting bowel habits in children with the IBS–constipation subtype.

13 April 2026 in Frontiers in Pediatrics
Verified
Journal Article
Open access
PDF file
MPMarisa Piccirillo
Marisa Piccirillo
GNGiovanni Di Nardo
Giovanni Di Nardo
EPEmanuela Pilozzi
Emanuela Pilozzi
SFSilvia Furio
Silvia Furio
VMVincenza Patrizia Di Marino
Vincenza Patrizia Di Marino
MMMaurizio Mennini
Maurizio Mennini
Background: Eosinophilic gastrointestinal diseases (EGIDs) are chronic, rare and heterogeneous disorders characterized by eosinophilic infiltration of gastrointestinal tract, resulting in gastrointestinal dysfunction. Although standard-of-care therapeutic strategies for eosinophilic esophagitis (EoE) are well-defined, limited evidence on successful treatment of eosinophilic gastrointestinal disorders beyond eosinophilic esophagitis (non-EoE EGIDs) in children is available. While dupilumab, a monoclonal antibody that inhibits interleukin (IL)-4 and IL-13 signaling, is currently approved in children with EoE, only anecdotal studies assessed its effects in children with non-EoE-EGIDs. Case presentation: This case report describes the successful use of dupilumab as a rescue therapy for a 14-year-old male with concurrent EoE and Eosinophilic Gastritis (EoG), unresponsive to dietetic approach. Despite initial responsiveness to steroid treatments, the patient experienced challenges in tapering off oral steroids without relapse. The administration of dupilumab at a dosage of 300 mg once a week led to clinical, endoscopic, and histological improvement after three months of therapy, highlighting its efficacy as a well-tolerated treatment option. Conclusions: The successful use of dupilumab as a single-therapy therapy in a steroid-dependent child, who did not respond to dietary interventions, highlights its potential in mitigating the development of steroid-related side effects. This report underscores the need for further research and clinical trials to deepen our understanding and optimize the use of dupilumab and other monoclonal antibodies in managing pediatric EGIDs, establishing a basis for the future development of treatment guidelines and protocols.

10 January 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
IMIsabella Madaffari*
Isabella Madaffari*
EMEdoardo Maria Muttillo
Edoardo Maria Muttillo
AFAlice La Franca
Alice La Franca
FMFanny Massimi
Fanny Massimi
GCGiorgio Castagnola
Giorgio Castagnola
Paolo MercantiniPaolo Mercantini
Paolo Mercantini
Background: Crohn’s disease (CD) is an inflammatory bowel disease (IBD) that also affects pediatric patients. It frequently presents as a localized disease, affecting the ileocecal area, ileum, or colon. It requires targeted therapy to achieve a good quality of life and long-term control of disease activity. Despite multiple medical therapies available, several patients benefit from surgical treatment. The aim of our study is to demonstrate how an early surgical approach can bring an improvement in disease activity, evaluating the Simple Endoscopic Score for Crohn’s Disease (SES-CD) and the Pediatric Crohn’s Disease Activity Index (PCDAI). Methods: A retrospective multicenter study was carried out from 2008 to 2023, including 29 patients, affected by localized CD. These data were analyzed: demographics, SES-CD, and PCDAI, before and after surgery. The differences between groups were analyzed using Student’s t-test for continuous variables, and Pearson’s Chi-squared test or Fisher’s exact test for categorical variables. Results: The SES-CD significantly decreased from 12 (median, range 1–15) to 0 (median, range 0–6) (p < 0.0001) and the PCDAI decreased from 30 (median, range 10–50) to 0 (median, range 0–15) (p < 0.0001). The rate of patients receiving enteral nutrition decreased from 51.7% preoperatively to 0% postoperatively (p = 0.0001). The rate of antibiotic use decreased from 13.8% to 0% (p = 0.0001). The rate of patients receiving ≥2 drugs decreased from 10.3% to 0% (p = 0.0001). Conclusions: The early surgical approach can be considered an excellent therapeutic strategy in patients with localized CD. Both parameters examined, SES-CD and PCDAI, demonstrated a clear improvement in the endoscopic images and in disease activity.

21 April 2026 in Frontiers in Pediatrics
Verified
Journal Article
Open access
PDF file
MPMarisa Piccirillo
Marisa Piccirillo
MMMaurizio Mennini
Maurizio Mennini
EFEnrico Felici
Enrico Felici
AMAngela Mauro
Angela Mauro
LBLuca Bernardo
Luca Bernardo
GNGiovanni Di Nardo
Giovanni Di Nardo
Background: Gastroesophageal reflux (GER) is a common physiological phenomenon in infants, typically self-limited, but often a source of parental concern. When non-pharmacological measures fail to improve symptoms, thickened formulas are commonly used. Zinc-L-carnosine (Polaprezinc) is a mucosal protectant with anti-inflammatory and antioxidant properties. It is widely used in gastrointestinal disorders in adults but has not yet been extensively studied in infants. We aim to evaluate the clinical effectiveness and cost impact of a Zinc-L-carnosine-based supplement (Hepilor liquido®) compared to thickened formula in infants with persistent regurgitation. Methods: This was a two-center, prospective, single-blind, randomized, non-inferiority study conducted in two Italian pediatric hospitals. Infants aged 4 weeks to 7 months with persistent regurgitation despite appropriate nutritional and behavioral management were randomized to receive either Hepilor liquido® or thickened formula for 8 weeks. The primary outcome was symptom improvement based on the I-GERQ-R (Infant Gastro-Esophageal Reflux Questionnaire-Revised) score. Secondary outcomes included a reduction in regurgitation frequency and treatment cost analysis. Results: Sixty infants aged 4 weeks to 7 months were randomized to receive either Hepilor liquido® ( n = 30, 50%) or thickened formula ( n = 30, 50%) for 8 weeks. Both groups showed significant improvement in I-GERQ-R scores at 8 weeks. Although no statistically significant difference was observed in overall symptomatic remission, the Hepilor liquido® group demonstrated a greater reduction in regurgitation frequency. Notably, the average treatment cost was significantly lower in the Hepilor® group compared to the thickened formula. No severe adverse events were recorded in both groups. Conclusions: Zinc-L-carnosine is a safe and effective alternative to thickened formula in treating persistent infant regurgitation, after the failure of non-pharmacological measures. Its lower cost and promising clinical effect support further investigation in larger pediatric cohorts. Clinical Trial Registration: https://clinicaltrials.gov/study/NCT06678997 , identifier: NCT06678997.